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ABSTRACT
for wide-neck aneurysms (15). Although the stent-assisted 
technique has been commonly used in the treatment of non-
hemorrhagic aneurysms, recently it is also being employed for 
the treatment of ruptured aneurysms. Stenting requires insti-
tution of treatment with dual antiplatelet agents (acetylsalicylic 
acid and clopidogrel) to avoid thromboembolic complications 
(1,16).
█    INTRODUCTION
About two-thirds of all patients with subarachnoid he-morrhage (SAH) following an aneurysm experience serious neurological complications or even death (20). 
In addition to conventional treatment using surgical clipping, 
endovascular coiling is an alternative treatment strategy 
(17,18). Intracranial stent-assisted coiling is useful particularly 
AIM: Stent assisted coiling (SAC) is an alternative in the treatment of ruptured aneurysms. Stenting requires the use of dual 
antiplatelet agents. Hydrocephalus is a complication of subarachnoid hemorrhage (SAH) and may require ventriculostomy. 
Antiplatelet treatment carries a risk of hemorrhage in ventriculostomy. The anti-aggregant effect starts at least four hours after the 
initial doses of treatment. However, in many studies, ventriculostomy was performed before antiplatelet treatment and hemorrhagic 
complications were related to the procedure. The aim of this study was to determine the risk of ventriculostomy related hemorrhage 
in patients with impaired thrombocyte function and to contribute to the literature. 
MATERIAL and METHODS: Between 2011 and 2016, 53 patients treated with SAC due to SAH in our clinic were retrospectively 
evaluated. Hemorrhagic complication risks due to antiplatelet therapy related to ventriculostomy were also evaluated.
RESULTS: All of the ventricular catheter procedures were performed at least 1 day after the dual therapy (in average 4.3 days 
after SAC). In 5 patients 1 ventriculostomy was performed, in 2 patients 2, and in 1 patient 6 ventriculostomies were performed. 
Although radiological hemorrhage was present on the catheter tract in 4 patients, no temporary or permanent neurological deficit 
was observed. 
CONCLUSION: Impaired thrombocyte functions pose a risk in ventriculostomy. Also, evaluating the risk of hemorrhage before the 
antiplatelet treatment reaches its full effect may lead to false results. Studies with small patient groups with anti-aggregant therapy 
and impaired thrombocyte functions also contribute to the literature. Larger studies regarding this subject are needed.        
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The risk of developing acute hydrocephalus following SAH 
is 20%, and it is usually treated with a ventriculostomy 
(11,13,21). The risk of ventriculostomy-related hemorrhage 
is low in patients without impairment of platelet function. 
Patients receiving dual antiplatelet therapy for prevention of 
stent thrombosis are at high risk of hemorrhage. However, 
these results were obtained from studies in which patients 
with unimpaired platelet function were evaluated (14,16,23). 
We aimed to contribute to the literature while evaluating 
the risk of ventriculostomy-related hemorrhage in patients 
who underwent stent-assisted coiling (SAC) with concurrent 
impairment in platelet function.
█    MATERIAL and METHODS
Patient Population and Procedural Technique
Our study was performed after a proposal was approved 
by the Institutional Review Board at the Baskent University, 
School of Medicine. We retrospectively evaluated data 
obtained from 53 patients treated using the SAC method 
for a ruptured aneurysm between June 2011 and April 2016. 
Informed consent was obtained from all patients included in 
the study, or from their relatives with regard to approval for 
administration of medications, and permission to perform 
interventional and surgical procedures. The study included 30 
women (mean age 50.2 years), and 23 men (mean age 51.08 
years). 
Six asymptomatic patients who demonstrated ventriculo-
megaly did not undergo a surgical procedure, and were not 
included in our study. Only eight patients who underwent 15 
ventriculostomies due to hydrocephalus following the SAC 
procedure for SAH were enrolled in the study. 
Angiographic evaluation determined the size of aneurysms 
and their morphology. A wide-neck aneurysm was defined as 
one having a dome-to-neck ratio <2:1 and/or a neck length 
>4 mm. In patients treated with SAC, 600 mg of clopidogrel 
and 100 mg of aspirin were administered as a loading dose 
via a nasogastric tube just prior to treatment, with a daily 
maintenance dose of 75 mg of clopidogrel and 100 mg aspirin. 
All patients were heparinized to maintain an activated clotting 
time of 250-300 seconds during the endovascular procedure. 
Heparinization was discontinued after the procedure, and 
patients were switched to low-molecular weight heparin. 
Platelet inhibition levels were confirmed using the rapid 
platelet function assay, viz. VerifyNow P2Y12 (Accumetrics, 
San Diego, California) the day after the procedure and on 
day 5. Low-molecular weight heparin administration was 
discontinued if therapeutic levels were noted to have been 
achieved (inhibition value >30%).
A standard ventriculostomy catheter (outer diameter 2.8 mm, 
PS Medical ventricular catheter, Medtronic) was advanced 5-6 
cm from Kocher’s point. A Ghajar guide (Neurodynamics, Inc.) 
was used in all patients.
Determination of Ventriculostomy-Related Hemorrhage
Computed tomography (CT) scans obtained in all patients 
were reviewed by a radiologist and a neurosurgeon. We 
evaluated 63 CT scans. Patients demonstrating hemorrhage 
in locations other than along the ventricular catheter tract 
were excluded from the study. Cerebral hemorrhage occurring 
along the catheter tract was considered to be related to the 
ventriculostomy (Figure 1A, B). A review of the patient’s 
medical records determined the clinical significance of the 
hemorrhage. Hemorrhage was classified as symptomatic 
if deterioration in neurological examination could not be 
attributed to pathological processes such as vasospasm, 
meningitis, or stroke, and was considered asymptomatic if the 
patient showed no changes on clinical examination. However, 
in some cases, ventriculostomy-related hemorrhage was 
diagnosed concurrently with severe vasospasm or meningitis. 
█    RESULTS
We retrospectively evaluated records obtained from 53 patients 
in whom SAC was used to treat ruptured aneurysms between 
June 2011 and April 2016. A ventriculostomy was performed 
in eight patients while they were concomitantly administered 
dual antiplatelet treatment. Patients were between 36-75 
years of age (mean 51.8 years). Of these patients (n=8), five 
showed aneurysms in the anterior circulation [two internal 
carotid artery (ICA) and three anterior communicating artery 
(ant-com)], two had aneurysms in the posterior circulation 
(two basilar dome), and one patient had two aneurysms of the 
anterior and posterior communicating arteries (ant-com and 
post-com). The Hunt-Hess score was 3 in six patients, and 4 
in two. Prior to ventriculostomy, the Fisher score on CT scan 
was noted to be 4 in all patients. Initial post-ventriculostomy 
CT scan was performed within the first 24 hours (Figure 2A, 
B). Ventricular drains were changed only if occluded or if 
infection was detected. However, no ventricular catheter was 
used for longer than a week. Patients who underwent long-
term drainage for a week had their catheters changed due to 
blockage. All ventricular catheter procedures were performed 
at least a day after the institution of dual therapy (mean of 
4.3 days after SAC). “Prothrombin time” or “activated clotting 
time” was determined in all patients prior to performing 
ventriculostomy procedures. All values were within normal 
limits. Patients with known bleeding diathesis were excluded 
from the study. One ventriculostomy was performed in 
five patients, 2 ventriculostomies in two patients, and 6 
ventriculostomies were performed in one patient. Although 
radiologically there was evidence of hemorrhage along the 
catheter tract in four patients, no temporary or permanent 
neurological deficit was observed. No deaths were related 
to complications associated with the ventriculostomy. 
Demographic data of the patients included in the study are 
presented in Table I.
█    DISCUSSION
Intracranial stents are used in the treatment of wide-neck 
aneurysms where conventional methods are insufficient. The 
use of a stent requires anti-aggregant treatment. Previously, 
use of anti-aggregant treatment was avoided due to the risk of 
possible hemorrhagic complications; however, this led to the 
risk of thromboembolic events (5,7-9).
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tract in such cases would not be attributable to platelet 
function impairment.
Numerous studies describe ventriculostomy-related hemorr-
hagic complications associated with endovascular treatment 
of intracranial aneurysms. Although relatively safe, ventricu-
lostomy is not a risk-free procedure. A meta-analysis involving 
1790 patients who underwent ventriculostomy reported the 
risk of hemorrhagic complications as 5.7%. However, the 
rate of clinically significant hemorrhage was 0.61%. Dual 
therapy was considered to be the most important risk fac-
tor associated with a ventriculostomy, and it is known to be 
catheter related. Kim et al., in a study performed on patients 
with SAH, reported that all hemorrhagic complications were 
secondary to ventriculostomies (7). Bodily et al., in a litera-
ture review, found that among 90 patients, 10 (11%) showed 
ventriculostomy-related hemorrhages. However, because the 
precise number of ventriculostomies performed on patients 
included in the study could not be determined, the reported 
rate was estimated to be approximately 3-10%. In this study, 
dual therapy had generally been administered following the 
ventriculostomy (4). Tumialan et al., in their case series which 
included seven patients, reported hemorrhagic complications 
in six (85%) patients. In this study, similar to the previously 
Reportedly, the rate of thromboembolic complications is 
7-15% (4,9). Although antiplatelet agents have been used in 
recent times for the prevention of these complications (2,3,5), 
their use has been associated with a higher risk of hemorrhagic 
complications. Data regarding complications in patients using 
dual antiplatelet therapy are primarily obtained from coronary 
artery related procedures; gastrointestinal and retroperitoneal 
hemorrhages have been commonly reported (8-10,12,24).
Previous studies have shown that clopidogrel use is dose 
dependant and a single dose of 600 mg causes major 
antiplatelet activity within 2 hours of use. Aspirin is rapidly 
absorbed from the stomach and upper gastrointestinal system 
with peak plasma concentrations attained within 30-40 minutes 
of intake resulting in inhibition of platelet function within an 
hour (19,25). However, in studies performed to determine 
the risk of hemorrhage in patients with a ventriculostomy 
with concurrent administration of dual therapy, it has been 
observed that in some patients, the ventriculostomy had been 
performed prior to administration of the dual therapy, while in 
some others, it was performed after dual therapy had been 
instituted (6). If patients are not administered dual therapy 
prior to SAC treatment and at the time of the ventriculostomy 
procedure, hemorrhagic changes observed along the catheter 
Figure 2A, B: CT scan 
(axial images) shows 
hydrocephalus and 
intraventricular catheter.
Figure 1: A) CT scan (axial 
slice) shows right frontal 
subcortical ventriculostomy-
related hemorrhage. 
B) Brain angiography after 
the stent coil was placed.
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in all patients who underwent a ventriculostomy. Patients 
who required acute interventions due to hydrocephaly were 
excluded from the study, and the risk of hemorrhage was 
evaluated using objective criteria. This fact distinguishes our 
study from previous ones. The rate of hemorrhage obtained 
in our study in patients without use of dual therapy is higher 
than rates determined previously. This can be accepted as 
evidence of the fact that concurrent dual therapy increases 
the risk of hemorrhage. Not all patients in our study presented 
with hydrocephalus; however, the presence of intraventricular 
hemorrhage was associated with a risk of hydrocephalus. 
Additionally, the need for ventriculostomy arose after the 
initiation of dual therapy.
Intraventricular hemorrhage is associated with a risk of 
hydrocephaly, and if a ventriculostomy is performed prior to 
platelet function impairment (institution of antiplatet therapy), 
the risk of complications is expected to be lower.
This study has limitations due to its retrospective nature, the 
relatively small patient population that was studied, and lack 
of comparison with a control group. Nevertheless, our study 
did demonstrate a definite risk of ventriculostomy-related 
hemorrhagic complications associated with platelet function 
inhibition.
█    CONCLUSION
Our study showed that patients treated with SAC in the 
presence of impaired platelet function might be at higher risk 
of hemorrhagic complications following a ventriculostomy. 
Studies demonstrating ventriculostomy-related risks of 
hemorrhagic complications owing to platelet dysfunction 
are very limited and clinical cases contributing to literature 
comprise small studies. Patients included in these studies 
had undergone a ventriculostomy before SAC was performed 
due to acute hydrocephalus. Thus, platelet inhibition had not 
yet occured. Due to the limited number of patients included 
in previous studies, as well as in ours, we propose that larger 
study samples would be required to obtain definitive evidence.
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